Answers are grounded in this paper and cite their sources.
<0.01). Our study suggests that denosumab may have a greater impact on serum calcium levels in patients with postmenopausal osteoporosis with higher baseline bone turnover than in patients with postmenopausal osteoporosis with normal baseline bone turnover, because maintenance of normal serum calcium in this subgroup is more dependent on bone resorption. Close monitoring of serum calcium levels is strongly recommended for denosumab-treated patients with high bone turnover, despite supplementation with activated vitamin D and oral calcium.
No takes yet. Share an insight, caveat, or question.
Ishikawa et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: